SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma - Quaterly Results

17 May 2022 Evaluate
A decent increase of about 49.58% in the sales to Rs. 1802.34 millions was observed for the quarter ended March 2022. The sales figure stood at Rs. 1204.94 millions during the year-ago period.The Total Profit for the quarter ended March 2022 of Rs. 1.39 millions grew from Rs.-59.54 millionsOperating profit for the quarter ended March 2022 rose to 312.25 millions as compared to 262.54 millions of corresponding quarter ended March 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 1802.34 1204.94 49.58 5569.74 4506.95 23.58 5569.74 4506.95 23.58
Other Income 17.47 25.36 -31.11 90.03 64.61 39.34 90.03 64.61 39.34
PBIDT 312.25 262.54 18.93 662.62 643.62 2.95 662.62 643.62 2.95
Interest 44.59 118.86 -62.49 320.12 513.36 -37.64 320.12 513.36 -37.64
PBDT 267.66 143.68 86.29 342.50 130.26 162.94 342.50 130.26 162.94
Depreciation 266.27 203.22 31.03 870.21 1088.99 -20.09 870.21 1088.99 -20.09
PBT 1.39 -59.54 -102.33 -527.71 -958.73 -44.96 -527.71 -958.73 -44.96
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 1.39 -59.54 -102.33 -527.71 -958.73 -44.96 -527.71 -958.73 -44.96
Equity 408.16 408.16 0.00 408.16 408.16 0.00 408.16 408.16 0.00
PBIDTM(%) 17.32 21.79 -20.49 11.90 14.28 -16.69 11.90 14.28 -16.69

Orchid Pharma Share Price

546.90 -23.60 (-4.14%)
20-Apr-2026 14:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.75
Dr. Reddys Lab 1233.95
Cipla 1231.60
Zydus Lifesciences 938.70
Lupin 2328.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×